nipah
viru
within
famili
paramyxovirida
wang
et
al
first
identifi
human
enceph
outbreak
malaysia
singapor
involv
least
case
death
chua
et
al
epidemiolog
link
fruit
bat
infect
pig
serv
amplifi
host
infect
human
close
contact
persontoperson
transmiss
rare
document
human
case
report
either
countri
detail
analys
environment
chang
trigger
outbreak
connect
wildlif
bat
livestock
pig
human
report
pulliam
et
al
daszak
et
al
triad
human
anim
environment
health
one
health
make
nipah
viru
outbreak
prime
exampl
term
associ
panepidem
anthropocen
lucey
et
al
nipah
viru
outbreak
persontoperson
transmiss
occur
repeatedli
rural
bangladesh
addit
nosocomi
outbreak
involv
peopl
hospit
siliguri
west
bengal
india
recogn
retrospect
chadha
et
al
smaller
outbreak
occur
west
bengal
persontoperson
transmiss
arankal
et
al
antibodi
nipah
viru
found
pteropu
giganteu
fruit
bat
haryana
state
northern
india
epstein
et
al
subsequ
outbreak
bangladesh
document
winter
month
past
year
associ
consumpt
human
date
palm
sap
occasion
liquor
date
palm
sap
contamin
nipah
viru
urin
saliva
fruit
bat
hegd
et
al
cort
et
al
pig
appear
play
role
human
infect
bangladesh
india
unlik
malaysia
singapor
howev
persontoperson
transmiss
nipah
viru
repeatedli
document
bangladesh
exampl
outbreak
patient
f
transmit
person
gurley
et
al
humantohuman
transmiss
link
close
contact
primarili
small
percentag
infect
person
exampl
person
nipah
infect
bangladesh
becam
ill
close
contact
anoth
person
nipah
possibl
role
respiratori
secret
transmiss
suggest
patient
nipah
bangladesh
often
pneumonia
well
enceph
hossain
et
al
viral
rna
frequent
identifi
respiratoryor
swab
hassan
et
al
note
nine
person
year
appear
respons
transmit
viru
person
person
lubi
et
al
b
overal
casefat
rate
estim
world
health
organ
approxim
whosearo
nipah
belt
describ
across
western
part
bangladesh
hahn
et
al
notabl
human
case
report
outbreak
capit
citi
dhaka
major
urban
area
importantli
howev
epstein
colleagu
recent
report
nipah
viru
rna
bat
exist
throughout
much
bangladesh
even
beyond
nipah
belt
note
niv
detect
restrict
nipah
belt
suggest
spillov
possibl
anywher
bangladesh
suitabl
strain
bathuman
interfac
present
epstein
et
al
taken
togeth
anticip
risk
undetect
outbreak
nipah
bangladesh
elsewher
asia
due
either
infect
travel
transmiss
bat
human
associ
persontoperson
transmiss
activ
anticip
action
taken
recognit
threat
exampl
manuscript
revis
firstev
nipah
outbreak
southern
india
report
may
kerala
laboratori
confirm
nipah
viru
infect
famili
commun
member
healthcar
worker
consist
persontoperson
transmiss
report
may
southeast
asia
region
offic
searo
updat
may
report
laboratoryconfirm
case
death
suspect
case
interim
assess
searo
major
outbreak
local
occurr
sourc
infect
assum
fruit
bat
although
laboratori
epidemiolog
investig
ongo
whosearo
may
much
larger
outbreak
nipah
rural
urban
anticip
especi
nation
lack
experi
nipah
bangladesh
malaysia
india
eg
myanmar
indonesia
nation
asia
middl
east
africa
prepar
nipah
outbreak
enhanc
order
avoid
unanticip
prevent
tragedi
urban
rural
ebola
panepidem
west
africa
unit
nation
report
result
person
report
ebola
viru
diseas
die
like
mani
death
occur
ebola
panepidem
due
unavail
healthcar
system
exist
ebola
emerg
lubi
discuss
pandem
potenti
nipah
lubi
concur
reemphas
call
action
especi
nipah
epidem
nation
prior
experi
nipah
analog
west
africa
ebola
similarli
urban
pneumon
plagu
upp
epidem
madagascar
approxim
person
diagnos
plagu
pneumonia
afro
term
afterward
tragic
opportun
improv
public
health
mead
unanticip
term
need
prepared
measur
either
urban
rural
outbreak
nipah
prepar
wherev
bat
host
viru
occur
bangladesh
least
part
india
eg
kerala
well
west
bengal
malaysia
singapor
indonesia
also
thailand
philippin
southern
thailand
nipah
viru
found
bat
howev
human
infect
document
sequenc
n
gene
bp
nipah
viru
show
ident
malaysian
strain
nipah
wacharapluesade
et
al
outbreak
nipah
viru
close
relat
henipaviru
occur
two
villag
mindanao
southern
philippin
person
met
case
definit
acut
enceph
one
mening
five
influenzalik
ill
unlik
outbreak
malaysia
panepidem
bangladesh
outbreak
mindanao
appear
involv
hors
transmit
viru
human
case
seven
involv
hors
slaughter
hors
meat
consumpt
five
provid
care
patient
either
hospit
transport
hospit
home
least
hors
die
includ
nine
acut
neurolog
ill
ching
et
al
laboratori
test
three
case
patient
reveal
neutral
antibodi
nipah
viru
igm
antibodi
consist
recent
nipah
viru
infect
realtim
pcr
serum
one
patient
posit
nipah
viru
spinal
fluid
second
patient
found
singl
sequenc
read
bp
p
gene
nipah
viru
short
sequenc
nt
ident
nipah
viru
isol
malaysia
ident
isol
bangladesh
ching
et
al
note
hors
australia
link
infect
hendra
viru
henipaviru
like
nipah
hendra
viru
discov
report
transmit
person
person
queensland
govern
unlik
nipah
nipahlik
viru
philippin
previou
report
link
nipah
virus
hors
two
polo
poni
report
infect
nipah
viru
malaysia
epidem
chua
et
al
separ
naturallyoccur
nipah
viru
outbreak
intent
releas
nipah
viru
also
recogn
potenti
risk
initi
octob
public
us
bipartisan
report
blue
ribbon
studi
panel
biodefens
includ
brief
scenario
hypothet
attack
washington
dc
locat
usa
abroad
due
genet
modifi
aerosol
nipah
viru
zoonot
one
health
natur
human
infect
nipah
viru
recogn
scenario
anim
death
occur
well
human
fatal
notabl
recommend
blue
ribbon
panel
recommend
number
integr
anim
health
one
health
approach
biodefens
strategi
lieberman
ridg
similarli
may
allday
larg
simul
exercis
call
clade
x
carri
post
onlin
john
hopkin
center
health
secur
hypothet
pathogen
bioengin
transmiss
hybrid
viru
gene
nipah
viru
human
parainfluenza
viru
intent
attack
began
caraca
venezuela
frankfurt
germani
spread
citi
via
intern
travel
januari
februari
includ
nipah
relat
henipavir
diseas
list
prioriti
diseas
invest
research
develop
diagnost
prevent
treatment
relat
announc
januari
nipah
viru
list
one
three
virus
along
lassa
viru
middl
east
respiratori
syndrom
coronaviru
merscov
would
priorit
new
coalit
epidem
prepared
innov
cepi
vaccin
develop
rottingen
et
al
current
us
food
drug
administr
fda
licens
nipah
vaccin
antivir
drug
immunotherapi
human
although
candid
exist
earli
stage
develop
broder
et
al
satterfield
et
al
least
one
person
usa
highrisk
laboratori
exposur
nipah
viru
receiv
experiment
neutral
monoclon
antibodi
term
nipah
viral
glycoprotein
g
emerg
use
basi
broder
et
al
australia
equin
vaccin
closelyrel
hendra
henipaviru
prevent
infect
hors
licens
sinc
broder
et
al
enhanc
prepared
measur
futur
urban
nipah
outbreak
includ
heighten
surveil
coordin
rapid
diagnost
test
train
exercis
includ
use
suffici
suppli
person
protect
equip
ppe
detail
isol
quarantin
protocol
clinic
manag
protocol
discuss
research
protocol
ethic
use
investig
therapi
vaccin
ebola
nipah
viru
report
occur
healthcar
facil
includ
infect
health
worker
burial
infect
corps
sazzad
et
al
timelin
acceler
develop
vaccin
also
immunebas
antibodi
therapi
antivir
drug
bossart
et
al
broder
et
al
geisbert
et
al
elshabrawi
et
al
satterfield
et
al
rottingen
et
al
prior
ebola
panepidem
west
africa
unlicens
earlystag
candid
ebola
vaccin
immunebas
antibodi
potenti
antivir
drug
case
today
three
type
nipah
viru
countermeasur
human
importantli
bangladesh
provid
detail
protocol
rahman
husain
nation
guidelin
fundament
issu
clinic
manag
prevent
control
nipah
viru
infect
nation
leadership
nation
experi
nipah
viru
outbreak
incorpor
intern
guidelin
prepared
mechan
exampl
may
recent
develop
open
onlin
cours
modul
mani
diseas
epidemicrel
topic
includ
teach
modul
nipah
viru
open
http
openwhoorgcours
gap
readili
close
collabor
nipah
expert
bangladesh
india
especi
kerala
elsewher
similarli
handbook
manag
epidem
deadli
diseas
includ
nipah
howev
could
readili
ad
provid
essenti
clinic
infect
prevent
control
inform
conclus
emphas
increas
geograph
rang
expand
epidemiolog
pattern
nipah
viru
asia
potenti
urban
outbreak
occur
near
futur
similar
situat
ebola
west
africa
licens
vaccin
antivir
drug
immunebas
antibodi
therapi
nipah
viru
although
earlystag
investig
candid
exist
three
type
countermeasur
unlik
panepidem
ebola
west
africa
anticip
urban
nipah
viru
epidem
also
take
comprehens
action
need
prepar
mitig
epidem
still
possibl
avoid
disast
like
prevent
tragedi
ebola
west
africa
unit
nation
report
fund
sourc
studi
sponsor
approv
requir
